Patents by Inventor Lori Westendorf

Lori Westendorf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLYPICAN 3 ANTIBODIES AND CONJUGATES THEREOF
    Publication number: 20240173427
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to GPC3 and conjugates thereof.
    Type: Application
    Filed: October 13, 2023
    Publication date: May 30, 2024
    Applicant: SEAGEN INC.
    Inventors: Travis Biechele, William Arthur, Patrick Burke, Lori Westendorf
  • BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS
    Publication number: 20240109975
    Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
    Type: Application
    Filed: August 15, 2023
    Publication date: April 4, 2024
    Applicant: SEAGEN INC.
    Inventors: Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
  • ANTI-AVB6 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20240076383
    Abstract: Provided are novel anti-av?6 antibodies and antibody-drug conjugates and methods of using such anti-av?6 antibodies and antibody-drug conjugates to treat cancer.
    Type: Application
    Filed: October 18, 2023
    Publication date: March 7, 2024
    Applicant: SEAGEN INC.
    Inventors: Maureen Ryan, Lori Westendorf, Eric Bradley Meyer, Heather Jean Kostner
  • ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20240033369
    Abstract: Provided are novel anti-CD228 antibodies and antibody-drug conjugates and methods of using such anti-CD228 antibodies and antibody-drug conjugates to treat cancer.
    Type: Application
    Filed: February 21, 2023
    Publication date: February 1, 2024
    Inventors: Sharsti SANDALL, Lori WESTENDORF, Timothy LEWIS
  • Anti-AVB6 antibodies and antibody-drug conjugates
    Patent number: 11827709
    Abstract: Provided are novel anti-?v?6 antibodies and antibody-drug conjugates and methods of using such anti-?v?6 antibodies and antibody-drug conjugates to treat cancer.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: November 28, 2023
    Assignee: Seagen Inc.
    Inventors: Maureen Ryan, Lori Westendorf, Eric Bradley Meyer, Heather Jean Kostner
  • Glypican 3 antibodies and conjugates thereof
    Patent number: 11819553
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to GPC3 and conjugates thereof.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: November 21, 2023
    Assignee: Seagen Inc.
    Inventors: Travis Biechele, William Arthur, Patrick Burke, Lori Westendorf
  • BCMA antibodies and use of same to treat cancer and immunological disorders
    Patent number: 11767365
    Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: September 26, 2023
    Assignee: Seagen Inc.
    Inventors: Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
  • ANTI-NTB-A ANTIBODIES AND RELATED COMPOSITIONS AND METHODS
    Publication number: 20230218776
    Abstract: Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells, such as multiple myeloma, non-Hodgkin lymphoma and acute myeloid leukemia.
    Type: Application
    Filed: November 23, 2022
    Publication date: July 13, 2023
    Applicant: SEAGEN INC.
    Inventors: Timothy Lewis, Lori Westendorf, Django Sussman, Che-Leung Law
  • Anti-CD228 antibodies and antibody-drug conjugates
    Patent number: 11617798
    Abstract: Provided are novel anti-CD228 antibodies and antibody-drug conjugates and methods of using such anti-CD228 antibodies and antibody-drug conjugates to treat cancer.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: April 4, 2023
    Assignee: Seagen Inc.
    Inventors: Sharsti Sandall, Lori Westendorf, Timothy Lewis
  • Methods of Purifying Masked Antibodies
    Publication number: 20220306727
    Abstract: The present invention relates to the field of antibody formulations. In particular, the present invention relates to specific methods of preparing masked antibodies with reduced aggregation. In some embodiments, the masked antibodies comprise anti-CD47 antibodies.
    Type: Application
    Filed: June 4, 2020
    Publication date: September 29, 2022
    Applicant: Seagen Inc.
    Inventors: Elise Cunningham, Susan Lee, Danielle Leiske, Catherine Eakin, Kevin Beam, Lori Westendorf, Michael Feldhaus, Samuel Pearce Alcoba
  • Masked Antibody Formulations
    Publication number: 20220233709
    Abstract: Formulations comprising masked antibodies are provided. In some embodiments, there is reduced aggregation of the masked antibodies in the formulations. In various embodiments, the formulations are pharmaceutical formulations suitable for use in therapeutic treatment.
    Type: Application
    Filed: June 4, 2020
    Publication date: July 28, 2022
    Applicant: Seagen Inc.
    Inventors: Danielle Leiske, Elise Cunningham, Shan Jiang, Lori Westendorf, Michael Feldhaus, Eoin Francis James Cosgrave, Catherine Marie Eakin
  • Anti-NTB-A antibodies and related compositions and methods
    Patent number: 11351269
    Abstract: Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells, such as multiple myeloma, non-Hodgkin lymphoma and acute myeloid leukemia.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: June 7, 2022
    Assignee: Seagen Inc.
    Inventors: Timothy Lewis, Lori Westendorf, Django Sussman, Che-Leung Law
  • CD47 Antibodies and Uses Thereof for Treating Cancer
    Publication number: 20220135674
    Abstract: Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.
    Type: Application
    Filed: October 20, 2021
    Publication date: May 5, 2022
    Applicant: Seagen Inc.
    Inventors: Shyra Gardai, Matthew Levengood, Vivian Trang, Lori Westendorf, Christopher Carosino, Che Leung-Law, Michael Feldhaus
  • BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS
    Publication number: 20220025062
    Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
    Type: Application
    Filed: June 25, 2021
    Publication date: January 27, 2022
    Applicant: SEAGEN INC.
    Inventors: Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
  • GLYPICAN 3 ANTIBODIES AND CONJUGATES THEREOF
    Publication number: 20210361776
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to GPC3 and conjugates thereof.
    Type: Application
    Filed: February 15, 2019
    Publication date: November 25, 2021
    Applicant: Seagen Inc.
    Inventors: Travis Biechele, William Arthur, Patrick Burke, Lori Westendorf
  • CD47 antibodies and uses thereof for treating cancer
    Patent number: 11180552
    Abstract: Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: November 23, 2021
    Assignee: Seagen Inc.
    Inventors: Shyra Gardai, Matthew Levengood, Vivian Trang, Lori Westendorf, Christopher Carosino, Che Leung-Law, Michael Feldhaus
  • BCMA antibodies and use of same to treat cancer and immunological disorders
    Patent number: 11078291
    Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: August 3, 2021
    Assignee: Seagen Inc.
    Inventors: Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
  • ANTI-AVB6 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20210198367
    Abstract: Provided are novel anti-?v?6 antibodies and antibody-drug conjugates and methods of using such anti-?v?6 antibodies and antibody-drug conjugates to treat cancer.
    Type: Application
    Filed: December 4, 2020
    Publication date: July 1, 2021
    Applicant: SEAGEN INC.
    Inventors: Maureen Ryan, Lori Westendorf, Eric Bradley Meyer, Heather Jean Kostner
  • CD123 Antibodies and Conjugates Thereof
    Publication number: 20210128742
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD123 and conjugates thereof.
    Type: Application
    Filed: January 5, 2021
    Publication date: May 6, 2021
    Applicant: Seagen Inc.
    Inventors: May Kung Sutherland, Lori Westendorf, Django Sussman
  • CD123 antibodies and conjugates thereof
    Patent number: 10912842
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD123 and conjugates thereof.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: February 9, 2021
    Assignee: Seattle Genetics, Inc.
    Inventors: May Kung Sutherland, Lori Westendorf, Django Sussman